New York, May 22, 2026, 09:06 (EDT)
- KalVista shares finished Thursday at $26.77, just under Chiesi’s cash bid of $27 a share.
- Funds tied to Frazier Life Sciences reported selling 3.0 million shares on May 19 at an average price of $26.7815.
- The tender offer will end one minute after 11:59 p.m. ET on June 10 unless it’s extended, according to .
KalVista Pharmaceuticals shares hovered under Chiesi Group’s $27 per share cash offer in early trading Friday on Nasdaq. A new filing showed an investor group tied to Frazier Life Sciences offloaded a sizable block of stock close to the offer level.
KALV trading now looks mostly like a merger-arbitrage bet, not a biotech play. The spread between KALV’s market price and its agreed buyout price stood at roughly 0.9% on Thursday, with shares at $26.77.
Frazier-linked holders sold 3 million KalVista shares on May 19, according to a May 21 Schedule 13D amendment. The sales averaged $26.7815, with prices between $26.77 and $26.825. The filing did not say why they sold.
Chiesi’s Skyline Merger Sub started a tender offer for all outstanding shares of KalVista at $27 a share in cash, a Schedule TO filing with the U.S. Securities and Exchange Commission showed. The KalVista board told shareholders to tender their stock into the offer.
Chiesi and KalVista said on April 29 they reached a $1.9 billion deal. Boards at both firms cleared the agreement, which still needs regulatory sign-offs and a majority of KalVista shares tendered before closing, expected in the third quarter of 2026.
The companies said there’s no financing condition on the offer. KalVista CEO Ben Palleiko said the board decided the deal “maximizes shareholder value.” Chiesi interim CEO Jean-Marc Bellemin said the buy will let Chiesi “accelerate impact in rare diseases.” KalVista Pharmaceuticals
EKTERLY, also called sebetralstat, is the asset in play. It’s an oral on-demand drug for hereditary angioedema, or HAE. The condition is a rare genetic disease that can trigger sudden and painful swelling attacks, sometimes affecting the airway.
KalVista posted $39.2 million in net product revenue and $40.9 million in total revenue for the quarter ended March 31. The company had no revenue in the same quarter last year. Net loss came in at $23.5 million, less than the $51.8 million loss reported a year ago.
HAE drug makers have drawn attention from rivals. Leerink Partners analyst Joseph Schwartz said HAE is a “hotbed for M&A” and called EKTERLY’s rollout “off to a very strong start.” Investor’s Business Daily pointed to Pharvaris and BioCryst-Astria as key comparisons on deals and pipeline moves. Investors
The spread here isn’t a guaranteed win. The deal might stall or fall through if not enough shares get tendered, regulators balk, closing conditions slip, or a rival makes a move; both firms listed EKTERLY commercialization and competition, plus integration issues after close, as risks. If the deal breaks, investors will be back to looking at KalVista as a regular commercial-stage biotech, not a near-cash buyout target.
The stock is stuck close to the bid for now. The key date is June 10, when the initial tender wraps up. Traders are looking for filings on who accepted, any big holders shifting, and if the offer gets extended.
